After closing Wednesday at $51.02, Seattle Genetics Inc. (SGEN) presents an attractive opportunity to get a 6.79% return in just 57 days, which is an annualized return of 43.49% (for comparison purposes only). To enter this trade, sell one Sep....

After closing Friday at $47.45, Seattle Genetics Inc. (SGEN) presents an attractive opportunity to get a 6.70% return in just 53 days, which is an annualized return of 46.12% (for comparison purposes only). To enter this trade, sell one Aug. '15...

The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artifical Intelligence Center found a trading opportunity with Seattle Genetics Inc. (SGEN) that should provide a 8.31% return in just 94 days. Sell one Sep....

Seattle Genetics and Unum Therapeutics said today they will team up to develop and commercialize new antibody-coupled T-cell receptor (ACTR) therapies for cancer. The deal could generate as much as $645 million for Unum.
The companies said...

For a hedged play on Seattle Genetics Inc. (SGEN) MarketIntelligenceCenter.com’s patented trade-picking algorithms selected a Sep. '15 $42.00 covered call for a net debit in the $38.39 area. That is also the break-even stock price for the...

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from multiple proprietary and collaborator antibody-drug conjugate (ADC) programs will be highlighted in more than 10 sessions at the American Society of Clinical Oncology (ASCO) 2015...

Oops! Unable to complete your request. Please refresh your browser.

See earlier news

Suggest other news sources for this topic

Topic

Top news source/blog that we're missing

Why do you recommend this news source?

RELATED WIKI ARTICLES

Related Articles

Seattle Genetics, Inc. is a biotechnology company developing monoclonal antibody-based therapies for treating cancer and autoimmune disease.[1] The company is working to develop next generation monoclonal therapies called antibody-drug conjugates (ADCs). The technology links potent synthetic drugs with monoclonal antibodies. The company has collaborations with major industry players all over the world such as: Millennium Pharmaceuticals, Bayer AG (BAYRY), Celldex Therapeutic (BER:TCE1), GlaxoSmithKline (GSK), Genentech (DNA), and quite a few others.[1] Leveraging these collaborations the company is working to navigate the high development costs and regulations that are indicative of the drug industry.

Business Growth

Seattle Genetics does not have any commercial products yet, but had revenue of $107.5 million for 2010. This was an increase of 107% from 2009. The company derived its revenue from payments that included technology access and maintenance fees, milestone and reimbursement payments from its collaborations. Its large jump from 2009 was primarily due to payments received from its collaborations with Genentech, Millennium, and other ADC collaborations.[1]

Trends and Forces

High Costs of Drug Development make it Difficult for Small Companies like Seattle Genetics

For more detailed information on the FDA approval process, see also Clinical trials.

Developing a new drug is a time-consuming and costly endeavor. Hundreds of thousands of candidate compounds must be screened to identify a handful of potential drugs, and even fewer of these candidate drugs are found to be effective at treating a disease. The drug must then pass strict safety standards in several series of clinical trials. The entire process of developing a new drug and bringing it to the market takes up to 10 to 15 years and on average costs $1.3 billion.[2]

Beginning in 2009, the FDA implemented a series of reforms that include stricter monitoring of drug adverse events, more funding for the agency, stronger ability to force product recalls, more scientific expertise within the agency, more transparency. Even before 2009 the result has been a much more conservative FDA, demanding more product information.[3]

Competition

The various aspects of patent protection and the extremely high costs of researching and developing drugs marks the pharmaceutical industry with high risk and high competitiveness. It is important to keep in mind when considering a comparison of industry players that competition does not arise between each company as a whole, but rather between specific drug areas and their relative advantages in therapeutic treatment. Due to this fact many of Seattle Genetic's collaborators are competitors since they are developing therapies in similar disease areas. They include: